Clinical trials: Castrate-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable…
- Trial name
- NCT05489991
- Testing
- TmPSMA-02
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tceleron Therapeutics, Inc.
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer.
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,
- Trial name
- PYRUS (NCT01692262)
- Testing
- Intermittent dosing of AZD5363
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of talazoparib for patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05650476
- Testing
- Talazoparib
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting.
- Trial name
- PROceed (NCT06380738)
- Where
- 36 sites in Germany
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
The purpose of this observational study of metastatic castration-resistant prostate cancer (mCRPC) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and…
- Trial name
- AQUARiUS (NCT02813408)
- Where
- 26 sites in Denmark, France and 1 more
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Castration-Resistant Prostatic Cancer
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen…
- Trial name
- NCT04404140
- Testing
- Ipatasertib, Atezolizumab, Docetaxel
- Where
- 9 sites in France, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC.
- Trial name
- NCT07594106
- Testing
- REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
- Where
- 6 sites in United States
- Volunteers
- 265 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Castration-resistant Prostate Cancer
HRR Prevalence in LatAm PROSPECT Study
Determine the prevalence of homologous recombination repair (HRR) gene mutations in participants with mCRPC in Latin America (LatAm) between February 2021 and January 2022.
- Trial name
- PROSPECT (NCT04962880)
- Where
- 11 sites in Argentina, Brazil and 5 more
- Volunteers
- 388 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP)…
- Trial name
- NCT05295927
- Testing
- EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone
- Where
- 4 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Prostate Cancer
Phase 1 of EC1169 In Patients With Recurrent MCRPC
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and…
- Trial name
- NCT02202447
- Testing
- EC1169, EC0652
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Hormone Refractory Prostate Cancer
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
- Trial name
- NCT00286806
- Testing
- AT-101
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ascenta Therapeutics
Hormone Refractory Prostate Cancer
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.
- Trial name
- HRPC (NCT00525408)
- Testing
- Mycobacterium w., Docetaxel
- Where
- 14 sites in India
- Volunteers
- 134 people
- Sponsor
- Cadila Pharnmaceuticals
Prostatic Neoplasms
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
This study was supposed to have assessed the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant.
- Trial name
- NCT01647789
- Testing
- CFG920
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Prostate Cancer, Neoplasm Metastasis
BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00337155
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Bayer